Mumbai-based Glenmark Pharmaceuticals has announced the launch of GLIPIQⓇ (semaglutide) in India for the management of Type 2 Diabetes Mellitus (T2DM), setting a new benchmark in affordability for GLP-1 therapy and expanding access to advanced diabetes treatment for patients.
GLIPIQⓇ is available in both vial and pre-filled pen formulations. The product has been approved by the Central Drugs Standard Control Organization (CDSCO) following a multicentre, randomised, comparative, active-controlled, open-label Phase III clinical study conducted in India, demonstrating favourable efficacy and safety outcomes in Indian patients with Type 2 diabetes.
The expected weekly cost of treatment with GLIPIQⓇ vials range from Rs 325 to Rs 440, significantly lowering the cost barrier to initiate GLP-1 therapy in India and establishing a more affordable entry point into this class of treatment.
In addition to vials, GLIPIQⓇ is also available in pre-filled pen format, offering convenience of self-dosing for long-term therapy. Together, the two formats – vial and pen – enable a structured treatment pathway. This approach supports continuity of care, improved adherence, and sustained treatment outcomes. Both presentations are available in strengths of 2 mg/1.5 mL, 4 mg/3 mL, and 8 mg/3 mL.
Glenmark is also introducing ‘Sankalp’, a patient support program (PSP) designed to support therapy initiations, improve comfort with injectable treatment, and enable long-term adherence. This reflects Glenmark’s commitment to not just improving affordability but enabling patients to stay on therapy and achieve better health outcomes.
